Vivek Subbiah and Michelle Rengarajan – “Identification of ICI – Induced Diabetes”

Vivek Subbiah shared on LinkedIn:

“Such a delight to host a podcast interview with Dr. Michelle Rengarajan,  Physician scientist at Harvard Medical School
and Mass General Brigham, the lead author of “Identification of Immune Checkpoint Inhibitor–Induced Diabetes,” recently published in JAMA Oncology

• In our discussion on American Medical Association Education hub
  we explore into the fascinating topic of how spontaneous autoimmunity can inform the incidence, risk factors, and clinical spectrum of a highly morbid adverse effect of immune checkpoint inhibitor (ICI) treatment, ICI-induced diabetes.
• This conversation is a must-listen for anyone interested in the cutting-edge intersections of oncology/ immunology/endocrinology

Link to podcast.”

Source: Vivek Subbiah/LinkedIn

Michelle Rengarajan is a physician-scientist and attending endocrinologist at Massachusetts General Hospital (MGH) and Harvard Medical School. She completed her M.D. and Ph.D. in the Medical Scientist Training Program at Stanford University. She has developed clinical and scientific expertise in both drug-induced and spontaneous autoimmune endocrinopathies, particularly autoimmune thyroid disease.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.